Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deffered Revenue: 2016-2023

Historic Non-Current Deffered Revenue for Akebia Therapeutics (AKBA) over the last 8 years, with Dec 2023 value amounting to $43.3 million.

  • Akebia Therapeutics' Non-Current Deffered Revenue changed negligibly% to $43.3 million in Q1 2024 from the same period last year, while for Mar 2024 it was $43.3 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $43.3 million for FY2023, which is negligibly% changed negligibly from last year.
  • As of FY2023, Akebia Therapeutics' Non-Current Deffered Revenue stood at $43.3 million, which was down 0.00% from $43.3 million recorded in FY2022.
  • Akebia Therapeutics' 5-year Non-Current Deffered Revenue high stood at $43.3 million for FY2022, and its period low was $21.5 million during FY2021.
  • In the last 3 years, Akebia Therapeutics' Non-Current Deffered Revenue had a median value of $43.3 million in 2023 and averaged $36.0 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Non-Current Deffered Revenue tumbled by 40.55% in 2019, and later skyrocketed by 101.62% in 2022.
  • Over the past 5 years, Akebia Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $33.1 million in 2019, then dropped by 23.48% to $25.3 million in 2020, then declined by 15.27% to $21.5 million in 2021, then skyrocketed by 101.62% to $43.3 million in 2022, then remained steady at $43.3 million in 2023.